Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11.
- 1 May 1999
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 276 (5) , H1769-H1779
- https://doi.org/10.1152/ajpheart.1999.276.5.h1769
Abstract
The respective role of angiotensin-converting enzyme (ACE) and neutral endopeptidase 24.11 (NEP) in the degradation of bradykinin (BK) has been studied in the infarcted and hypertrophied rat heart. Myocardial infarction (MI) was induced in rats by left descendant coronary artery ligature. Animals were killed, and hearts were sampled 1, 4, and 35 days post-MI. BK metabolism was assessed by incubating synthetic BK with heart membranes from sham hearts and infarcted (scar) and noninfarcted regions of infarcted hearts. The half-life ( t ½) of BK showed significant differences among the three types of tissue at 4 days [sham heart (114 ± 7 s) > noninfarcted region (85 ± 4 s) > infarcted region (28 ± 2 s)] and 35 days post-MI [sham heart (143 ± 6 s) = noninfarcted region (137 ± 9 s) > infarcted region (55 ± 4 s)]. No difference was observed at 1 day post-MI. The participation of ACE and NEP in the metabolism of BK was defined by preincubation of the membrane preparations with enalaprilat, an ACE inhibitor, and omapatrilat, a vasopeptidase inhibitor that acts by combined inhibition of NEP and ACE. Enalaprilat significantly prevented the rapid degradation of BK in every tissue type and at every sampling time. Moreover, omapatrilat significantly increased the t ½ of BK compared with enalaprilat in every tissue type and at every sampling time. These results demonstrate that experimental MI followed by left ventricular dysfunction significantly modifies the metabolism of exogenous BK by heart membranes. ACE and NEP participate in the degradation of BK since both enalaprilat and omapatrilat have potentiating effects on the t ½ of BK.Keywords
This publication has 27 references indexed in Scilit:
- Effect of Neutral Endopeptidase 24.11 Inhibition on Myocardial Ischemia/Reperfusion Injury: The Role of KininsJournal of Cardiovascular Pharmacology, 1997
- In Vivo Pharmacology of Dual Neutral Endopeptidase/Angiotensin-Converting Enzyme InhibitorsJournal of Cardiovascular Pharmacology, 1996
- Human neutrophil and plasma endopeptidase 24.11: quantification and respective roles in atrial natriuretic peptide hydrolysisEuropean Journal of Clinical Investigation, 1995
- Development of digoxigenin-labeled peptide: Application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissuesPeptides, 1994
- A local kallikrein-kinin system is present in rat hearts.Hypertension, 1994
- Markedly different effects on ventricular remodelling result in a decrease in inducibility of ventricular arrhythmiasJournal of the American College of Cardiology, 1994
- Progressive ventricular dilation in experimental myocardial infarction and its attenuation by angiotensin-converting enzyme inhibitionThe American Journal of Cardiology, 1991
- CHANGES IN CARDIAC ANGIOTENSIN CONVERTING ENZYME AFTER MYOCARDIAL INFARCTION AND HYPERTROPHY IN RATSClinical and Experimental Pharmacology and Physiology, 1991
- Basic carboxypeptidases: regulators of peptide hormone activityTrends in Pharmacological Sciences, 1988
- Kinin Formation: Mechanisms and Role in Inflammatory DisordersAnnual Review of Immunology, 1988